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Abstract
Introduction: Induced hypothermia has been shown to improve outcome after cardiac arrest, but early
prognostication is hampered by the need for sedation. Here we tested whether a biomarker for
neurodegeneration, the neurofilament heavy chain (NfH), may improve diagnostic accuracy in the first days after
cardiac arrest.
Methods: This prospective study included 90 consecutive patients treated with hypothermia after cardiac arrest.
Plasma levels of phosphorylated NfH (SMI35) were quantified using standard ELISA over a period of 72 h after
cardiac arrest. The primary outcome was the dichotomized Cerebral Performance Categories scale (CPC). A best
CPC 1-2 during 6 months follow-up was considered a good outcome, a best CPC of 3-4 a poor outcome. Receiver
operator characteristics and area under the curve were calculated.
Results: The median age of the patients was 65 years, and 63 (70%) were male. A cardiac aetiology was identified
in 62 cases (69%). 77 patients (86%) had out-of-hospital cardiac arrest. The outcome was good in 48 and poor in
42 patients. Plasma NfH levels were significantly higher 2 and 36 hours after cardiac arrest in patients with poor
outcome (median 0.28 ng/mL and 0.5 ng/mL, respectively) compared to those with good outcome (0 ng/mL, p =
0.016, p < 0.005, respectively). The respective AUC were 0.72 and 0.71.
Conclusions: Plasma NfH levels correlate to neurological prognosis following cardiac arrest. In this study, 15
patients had neurological co-morbidities and there was a considerable overlap of data. As such, neurofilament
should not be used for routine neuroprognostication until more data are available.
Introduction
Post cardiac arrest intensive care is complex and the
dynamic multi-organ failure is often referred to as the
post-resuscitation syndrome [1]. The major cause of
death in patients with return of spontaneous circulation
(ROSC) is ischemic brain damage [2], which evolves over
several days [3]. In many patients who remain comatose
after cardiac arrest, a reliable assessment of neurological
prognosis therefore needs to be postponed by several
days [4-6]. The use of induced hypothermia to improve
outcomes has further complicated matters because it
mandates sedation and intermittent use of muscle relax-
ants during the intervention. Moreover, hypothermia
delays the metabolism of drugs [7] and makes a clinical
neurological examination less reliable [8,9]. Therefore,
we need to reassess and improve our prognostic instru-
ments and explore novel and complementary methods of
a clinical neurological examination [10].
Several biomarkers have been evaluated to assess brain
damage after cardiac arrest with inconsistent results -
for example, neuronspecific enolase (NSE), S-100B, and
glial fibrillary acidic protein (GFAP) [5,11-13]. Among
these, NSE and S-100B are the most extensively studied
and NSE is the only one that has been integrated into
clinical guidelines [6]. Although highly correlated to the
extent of ischemic brain injury [10], weaknesses with
NSE include its sensitivity to false positives due to sam-
ple hemolysis and the lack of a standard [14,15]. The
advantage of a high sensitivity of blood S-100B levels for
parenchymal brain damage is hampered by a lower
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specificity due to presence in extra-nervous system tis-
sues such as bone marrow and fatty tissue [16,17].
The neurofilament heavy chain (NfH) is a specific pro-
tein biomarker of neurons and axons [18]. This 190 to
210 kDa protein of various degrees of phosphorylation
is an obligate heteropolymer with the Nf light (NfL) and
medium (NfM) chains. Together NfH, NfL and NfM
belong to the class IV group of intermediate filaments,
which support the axonal cytoskeleton [18]. Accumula-
tion or increased levels of NfH and NfL were observed
in a number of diseases including stroke and cardiac
arrest [18-24].
To investigate the time-course of NfH release and its
prognostic value, we studied serial plasma samples in a
cohort of hypothermia-treated cardiac arrest patients.
Materials and methods
This prospective study was performed in the general and
cardio-thoracic ICUs of Lund University Hospital, Swe-
den, from August 2003 to March 2007. The study was
approved by the Regional Ethical Review Board at Lund
University (411/2004, 223/2008), and informed consent
was sought from next of kin or, retrospectively, from
the patient.
Epidemiological data and cardiac arrest data were col-
lected prospectively. All cardiac arrest patients, regard-
less of location of arrest or initial rhythm, with ROSC
and sustained unconsciousness (Glasgow coma scale
(GCS) ≤7), were considered for induced hypothermia.
Exclusion criteria for hypothermia treatment were term-
inal disease, intracerebral hemorrhage, aortic dissection,
or major trauma. Hypothermia was initiated as soon as
possible after ROSC in the emergency room or catheter-
ization laboratory using 30 ml/kg cold saline and subse-
quent treatment in the ICU was performed as described
earlier [25].
A cardiologist initially evaluated all patients. Urgent
angiography, percutaneous cardiac intervention and, if
necessary, circulatory support using intraaortic balloon
pump counter pulsations was undertaken when indi-
cated. Patients received hypothermia for 24 hours at 33
+/-1°C and rewarming was controlled at 0.5°C/hour.
Patients were sedated using propofol 2 to 4 mg/kg/hour
and fentanyl 1 to 3 μg/kg/hour [25].
In patients remaining comatose, full intensive care was
provided for at least three days after normothermia, at
which time a clinical neurological evaluation was per-
formed. In addition, somatosensory evoked potentials
(SSEP), amplitude-integrated electroencephalogram
(aEEG) and diffusion-weighted magnetic resonance ima-
ging (DW-MRI) were added as a basis for a decision on
level of care [10]. The patients were evaluated at ICU
and hospital discharge by an intensivist, and by a neu-
rologist six months later, using the five-graded Cerebral
Performance Categories (CPC) scale: CPC 1 = good cer-
ebral performance, CPC 2 = moderate cerebral disabil-
ity, independent, CPC 3 = severe cerebral disability,
conscious but dependent, CPC 4 = coma, CPC 5 =
death [26]. To assess for clinically relevant neurological
injury, the best CPC score during six months follow up
was regarded as the primary outcome. A best CPC score
of 1 to 2 at any time was considered a good outcome
and a best CPC of 3 to 4 a poor outcome. Our second-
ary outcome was survival at six months.
As the release profile of soluble NfH after cardiac arrest
was not known, we chose to collect several samples over
the first three days to assess the release profile in a simi-
lar fashion as previously done for neuron-specific enolase
and S-100B [12], thus in part using a cohort on which we
have previously published. Plasma-samples for soluble
neurofilament analysis were collected at admission and at
2, 6, 12, 24, 36, 48, and 72 hours after cardiac arrest. The
plasma samples were centrifuged and frozen (-70°C)
immediately after collection. After the end of the study,
samples were thawed once, centrifuged at 4,000 rpm for
five minutes, aliquoted, and refrozen (-70°C) for later
analysis. During aliquoting, the samples were kept on ice.
We compared the levels of plasma NfH with the pre-
viously analysed levels of plasma NSE at the 48 hour
time-point. This time-point for NSE was chosen because
it had the best sensitivity/specificity for a poor prognosis
in our previous Receiver Operating Characteristic (ROC)
curve analysis [12]. Levels of plasma NfH were also com-
pared with the results of SSEP-recordings approximately
72 hours after normothermia.
NfH ELISA
All samples were coded. Plasma NfH levels were mea-
sured in duplicates with the analyst being blinded to all
other information using a standard in-house ELISA [27].
Adhering to a previously proposed nomenclature the
capture antibody (SMI 35 for variously phosphorylated
NfH) is shown in the superscript as NfHSMI35. To mini-
mize the analytical error all samples were batch analysed
[28]. Batch analysis improved the analytical error (coeffi-
cient of variation) to 5.4% in the present study. The
reported sensitivity of the ELISA is 0.2 ng/mL [27]. Fol-
lowing batch analysis the detection limit in this study
was 0.001 ng/mL. Non-measurable NfHSMI35 levels were
reported as 0 ng/mL.
Statistical analysis
The coded biomarker data and clinical data were elec-
tronically transferred to a third centre (Department of
Neurosurgery, Copenhagen University, Denmark). Only
after merging all code data the joint dataset was released
to the investigators for analysis of the predefined
hypotheses. Statistical analysis was performed using the
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SPSS software software version 15.0 (SPSS Inc., Chicago,
IL, USA). Continuous data are presented as median and
inter quartile range (IQR). Categorical data are given as
counts and percentages. The material was dichotomized
using the primary endpoints good (best CPC 1 to 2 dur-
ing six months follow up), and poor neurological out-
come (best CPC 3 to 4 during six months follow up).
The data were not normally distributed, consequently
non-parametrical statistics were used. The Mann Whit-
ney U test was used to assess differences between the
good and poor outcome groups at the different time-
points. Bonferroni-corrections were used to correct for
multiple comparisons. Correlations between continuous
variables were assessed using Spearman correlation. Chi
squared test was used to compare frequencies. ROC
analysis was performed. P < 0.05 was considered
significant.
Results
Ninety-two patients were included and two were
excluded due to all samples missing (n = 1) and failed
analysis (n = 1), resulting in 90 remaining patients. For
patient characteristics, see Table 1. The median time
from cardiac arrest to return of spontaneous circulation
was 20 minutes (IQR 14 to 30 minutes). Therapeutic
hypothermia was induced at a median of 66 minutes
(IQR 54 to 94 minutes) after cardiac arrest, and goal
temperature was reached at a median of 210 minutes
(IQR 135 to 295 minutes). Forty-eight patients (53%)
had a good outcome, defined as best CPC 1 to 2 during
follow up, and 42 (47%) had a poor outcome. At six
months follow up, 46 patients were still alive in the
good outcome group and one more in the poor out-
come group resulting in a six-month survival of 52% (47
of 90). For time and cause of death and withdrawal of
intensive care, see Table 2. The patients were heteroge-
neous with regard to their past medical history with sig-
nificant co-morbidity. Fifteen of the included patients
had a previously known neurological disease; stroke or
intracranial bleeding for more than one year ago (n =
8), epilepsy (n = 2), posttraumatic para-paresis (n = 1),
diabetes with polyneuropathy (n = 1), Guillian-Barré
syndrome (n = 1), diffuse memory problems (n = 1),
and placement of a ventriculoperitoneal shunt for post-
traumatic hydrocephalus (n = 1).
A total of 591 samples were collected from the 90
patients (Table 3). The main reasons for missing sam-
ples were due to intra- or inter-hospital transfer (early
samples), patients dying or regaining consciousness and
physically leaving the ICU (late samples).
After Bonferroni corrections, there were significant
differences between the good and the poor outcome
groups at two hours (P = 0.016) and 36 hours (P <
0.005) after cardiac arrest. Plasma NfHSMI35 levels were
also detectable following cardiac arrest in patients with
a good clinical outcome. Due to overlapping NfHSMI35
values, no clinically meaningful cut-off levels separating
the good and the poor outcome groups could be identi-
fied (Figure 1). The ROC-analysis showed the highest
area under curve (AUC) for two hours (AUC 0.72, 95%
confidence interval (CI) 0.54 to 0.90), 36 hours (AUC
0.71, 95% CI 0.52 to 0.90) and 72 hours (AUC 0.68, 95%
CI 0.50 to 0.88) respectively (Figure 2). The AUC for
the other measurement times were 0.51 to 0.60 also
with wide CIs. Regarding six months survival, a group
difference remained after Bonferroni corrections at 36
hours (P = 0.008) but was also significant at 72 hours (P
= 0.04) after cardiac arrest. The plasma NfHSMI35 con-
centration at 36 hours was selected for comparison with
NSE at 48 hours to limit the number of comparisons,
Table 1 Patient characteristics
Good outcome, n = 48 Poor outcome, n = 42 P value
Age (median, IQR) 62 (50-73) 71 (52-78) 0.062
Male sex 37 (88%) 26 (62%) 0.166
Out-of-hospital cardiac arrest 41 (85%) 36 (86%) 1.000
Initial rhythm VT/VF (n = 85) 35 (78%) 23 (58%) 0.001
Cardiac cause 39 (81%) 23 (55%) 0.011
n = 90, if not otherwise stated
Good outcome is defined as a best cerebral performance categories scale 1 to 2 during six months follow up; P value from Mann Whitney U test (age), Fisher’s
exact test for remaining comparisons.
IQR, inter quartile range; VT/VF, pulse-less ventricular tachycardia or ventricular fibrillation.
Table 2 Time and cause of death
Circulatory/MOF Neurological Other
Number of patients 8 33 2




Time of withdrawal (d) NA 6 (3-10) NA
Assessment of cause of death in dying patients, including time of death, the
number of patients where intensive care was withdrawn, and time of
withdrawal. In patients where intensive care was withdrawn due to
neurological reasons the cause of death was assessed as due to neurological
reasons. Other includes premorbid disease and other interfering disease
(septicaemia) unrelated to the cardiac arrest. Time is shown in days (d) as
median (range). NA = not applicable; MOF = Multi-organ failure
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but no significant correlation was found (P = 0.068, data
not shown). Plasma NfHSMI35 levels at 36 hours were
not significantly different between patients lacking SSEP
bilaterally and patients with at least unilateral identifi-
able N20 peaks (data not shown).
In approximately one third of the patients the cardiac
arrest was of non-cardiac cause (asphyxia/respiratory
failure (n = 9), pulmonary embolism (n = 5), hanging
and drowning (n = 3), hyperkalemia (n = 1), alcohol/epi-
lepsy/acidosis (n = 3), and unknown (n = 5)). A post hoc
analysis of the NfH values using only the patients with
cardiac arrest of a cardiac cause (n = 62) was made. The
results after Bonferroni-corrections (x8) were significant
for two hours (P = 0.008), 24 hours (P = 0.048), and 36
hours (P < 0.005). As in the primary analysis no cut-off
values were identifiable.
Discussion
This study evaluated serial samples of NfHSMI35 in
plasma from patients resuscitated after cardiac arrest
and treated with induced hypothermia. The main find-
ings were that NfHSMI35 was measurable in plasma from
patients with poor as well as a good outcome, with sig-
nificantly higher acute levels (2 and 36 hours) in the
poor outcome group. The respective AUC (0.72 and
0.71) were promising but the considerable overlap of
data between the groups precluded calculation of a defi-
nite cut-off value to be recommended for use in indivi-
dual patients.
An ideal biomarker should be easily collected and is,
in practice, often drawn from blood. Regarding biomar-
kers assessing neurological damage, the cerebrospinal
(CSF) compartment may allow for more specific detec-
tion of central nervous system-related damage and is
therefore often used [22,29]. Patients exposed to modern
cardiac care, including most cardiac arrest patients, are
heavily anti-coagulated and exposed to drugs affecting
platelet function as well as low molecular weight
heparin. This contraindicates lumbar puncture for col-
lection of CSF due to the risk of epidural hematoma. In
Table 3 Plasma NfHSMI35 and neurological outcome
Good outcome, n = 48 Poor Outcome, n = 42
Time n Median IQR Range n median IQR Range P value
Acute 29 0 0-0.25 0-3.96 28 0.05 0-0.21 0-2.47 0.586
2 h 38 0 0-0.20 0-2.35 29 0.28 0.03-0.69 0-2.83 0.002
6 h 40 0 0-0.06 0-9.21 35 0 0-0.19 0-1.35 0.569
12 h 45 0 0-0.03 0-6.96 40 0 0-0.13 0-1.21 0.172
24 h 43 0 0-0.03 0-3.96 39 0 0-0.11 0-4.82 0.035
36 h 42 0 0-0 0-0.57 34 0.05 0-0.26 0-4.14 0.000
48 h 45 0 0-0.03 0-1.20 33 0.04 0-0.15 0-0.89 0.059
72 h 40 0 0-0.02 0-1.81 31 0.01 0-0.24 0-2.23 0.024
h, hours after cardiac arrest; IQR, interquartile range; NfH, neurofilament heavy chain; P, Mann-Whitney U-tests without Bonferroni corrections.
Figure 1 Box-plot comparing good and poor outcome groups
of patients at the different sampling times. Boxes show the inter
quartile range with median marked in the box, whiskers denote
values within 1.5 times the interquartile range. Outliers are omitted.
CA, cardiac arrest; NfH, neurofilament heavy chain.
Figure 2 ROC-curve showing 2, 36 and 72 hours after the
cardiac arrest. NfH, neurofilament heavy chain; ROC, receiver
operating characteristic.
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the ICU setting, there is instead a considerable advan-
tage in blood sampling, allowing for serial measure-
ments, reducing the risk of making an erroneous
decision based on one single sample. Hence, although
the CSF may be a more relevant compartment, assess-
ment of biochemical neuro-markers in cardiac arrest
patients is better performed in blood.
NfH is a large protein with a molecular weight of 190
to 210 kD depending on the degree of phosphorylation
[18]. Following neuro-axonal injury NfH is released into
the extracellular fluid from where it can be measured
using ELISA [30]. From the extracellular fluid NfH dif-
fuses into the CSF compartment. From the CSF, NfH
reaches the blood via the blood CSF barrier at the lum-
bar level or it may diffuse directly through the cortical
arachnoid villi to the blood stream [29]. The physiologi-
cal wash out pattern of NfHSMI35 from the CSF is not
known in cardiac arrest. For reasons already discussed,
it was not possible to evaluate the assessment of
NfHSMI35 kinetic from the CSF to the blood in this
study.
Our time-course analysis showed an initial increase in
plasma levels of NfH, with significant differences
between the good and the poor outcome groups as early
as two hours after cardiac arrest (Figure 1). This may
reflect early neuronal damage [30]. From experimental
data it was shown that blood NfH levels reach their
peak between 30 minutes and two hours after ‘cardiac
arrest’ [19]. This fits well with the in vivo human data
from this study. Alternatively, NfHSMI35 could be
released from peripheral axons [18,19] damaged during
resuscitation. The levels of plasma NfHSMI35 in our
study were similar to those seen within six hours after a
mild stroke [23]. However, despite a uniform protein
standard, one needs to be cautious when comparing
these studies, because one was performed from serum
and the other from plasma. The long-term temporal
dynamics of blood NfH following cardiac arrest are less
well known. A secondary increase of NfHSMI35 occurred
in the poor outcome group at later sampling times
(Figure 1). We also found significant differences between
NfH SMI35 levels in surviving and dying patients at 36
and 72 hours after cardiac arrest. This delayed release of
NfH in this exploratory study fits with the delayed apop-
totic cell death pattern described in experimental mod-
els of CA [3] and with the release pattern of the more
established biomarker NSE, which peaks at 48 to 72
hours after the cardiac arrest [12]. Part of the lack of
significance may relate to the fact that approximately
one third of the patients had cardiac arrests of non-car-
diac cause, as suggested by the post hoc subgroup analy-
sis. It is also possible that complications in the post-
arrest period add to development of secondary brain
damage contributing to the later rise in blood levels
Still, we were not able to identify any cut-off levels or
predictive values to be recommended for individual
patients due to a considerable data overlap. One reason
may be that sampling was stopped at 72 hours after car-
diac arrest and that the optimal time for NfH sampling
thereby may have been missed. An increase in NfHSMI35
approximately one week after subarachnoidal hemor-
rhage has been observed in ventricular CSF [31] and a
recent study showed that NfHSMI35 levels increased in
serum three weeks after stroke [32]. From a practical
point of view, a later maximum level of NfH SMI35 (> 1
week) is of less value for the acute prognostication and
the decision on level of care. As the sensitivity of estab-
lished methods for neurological prognostication, such as
SSEP, is limited, biomarkers, such as serum NfHSMI35
may provide complimentary information. We did not,
however, find NfHSMI35 levels to be related to a lost
SSEP N20 potential or to the serum levels of NSE. In a
previous study we found NSE to correlate well with
neurological outcome [12], SSEP, diffusion-weighted
MRI and also neuropathology in a fraction of the pre-
sent cohort [10]. It is possible that the heterogeneous
patient population and methodological limitations
further discussed below, might have affected the results
of the analyses. A future, larger prospective study with a
prolonged sampling may allow to address these issues.
Such a study should also include an appropriate control
group without neurological co-morbidities to allow for
better calculation of a cut-off level.
Limitations of the study
In this study, the neurofilament analyses were per-
formed on stored samples and the results were not
available during the treatment and evaluation of
patients, and have thus not influenced clinical decision-
making. We encountered large variability of the plasma
levels of NfH, which can be noted in the range of values
in Table 3. Occasional values in one patient were high
without an apparent clinical correlate and occasional
patients with definite brain damage did not have mea-
surable plasma levels of NfH. This variability needs to
be taken into account when planning future studies.
Long-term storing and handling of samples may have
affected NfHSMI35 levels and contributed to the
variability.
As presented in the results section, some (n = 15) of
the patients had neurological comorbidities. Importantly,
in all of these co-morbidities, an increase of NfHSMI35
levels has been described. In an experimental setting
these limitations can be overcome, revealing a more
meaningful temporal time course of blood NfHSMI35
levels [19], but this is not realistic for clinical practice.
The relevance of pre-existing neurological co-morbidity
is further underlined by a post-hoc analysis showing
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significant difference in plasma NfHSMI35 levels 36 hours
after cardiac arrest between the patients with previous
neurological disease compared with the ones without (P
= 0.018, n = 76). We speculate that an already injured
brain may be more vulnerable to ischemic damage fol-
lowing cardiac arrest but the present study was under-
powered to investigate this post-hoc hypothesis. The
presence of anti-neurofilament auto-antibodies may
have masked the relevant binding epitopes for the
ELISA causing false-negative results [18] but this was
not investigated. Could injury to the peripheral nervous
system have caused an increase of plasma NfHSMI35
levels? This is a possibility and has been discussed else-
where [29]. Particularly in patients with significant vas-
cular co-morbidity and diabetes there is an increased
likelihood for presence of coexisting peripheral neuropa-
thy. Taken together these pre-analytical and analytical
problems need to be taken into account for the inter-
pretation of plasma NFHSMI35 levels.
Conclusions
Plasma NfH SMI35 levels were quantifiable in comatose
patients after cardiac arrest. The plasma levels were sig-
nificantly higher levels in the poor outcome group as
compared with the good outcome group in the early
phase after cardiac arrest when sedation limits the clini-
cal assessment. Due to a considerable overlap between
the groups no clinically relevant cut-off level could be
proposed. It is too early to recommend the routine use
of plasma NfH SMI35 in this context for clinical decision-
making.
Key messages
• NfH SMI35 is quantifiable in plasma after cardiac
arrest.
• Levels are significantly higher in the poor outcome
group at 2 and 36 hours after cardiac arrest.
• This exploratory study needs validation in a larger
and more homogenous cohort before plasma NfH can
be recommended for routine neuroprognostication.
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